Precision Medicine in the CICU: Identifying Proteomic Biomarkers

Not yet recruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

April 15, 2027

Conditions
Congenital Heart Disease
Interventions
DIAGNOSTIC_TEST

Somascan 5.0

This observational study will test patient plasma using the SomaScan platform, a highly multiplexed proteomic tool that uses SOMAmers (Slow Off-rate Modified Aptamers) to bind with high specificity and affinity to preselected proteins to quantify levels. SomaScan v5.0 quantifies 10,778 clinically relevant human proteins, with several thousand proteins linked to inflammation and immune system functions, across a wide range of concentrations (\>10 logs) with high sensitivity (\<1 pg/mL) and reproducibility (median coefficient of variation \< 5%). Individual protein concentrations are transformed into a corresponding SOMAmer concentration and quantified using a DNA microarray read-out.

Trial Locations (1)

02115

Boston Children's Hospital, Boston

All Listed Sponsors
lead

Boston Children's Hospital

OTHER

NCT06642662 - Precision Medicine in the CICU: Identifying Proteomic Biomarkers | Biotech Hunter | Biotech Hunter